SCHEMBL5117969

SCHEMBL5117969

O=C1Nc2cccc(Cl)c2C(c2ccc(F)cc2)O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PBRM1 Q86U86 4/20 0.41
▸ SMARCA2 P51531 2/20 0.41
▸ SMARCA4 P51532 2/20 0.41
▸ CA2 P00918 1/20 0.40
▸ TP53 P04637 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ FADS1 O60427 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ HTR5A P47898 7/20 0.35
▸ HTR1A P08908 5/20 0.35
▸ HTR1D P28221 5/20 0.35
▸ HTR2C P28335 5/20 0.35
▸ HTR7 P34969 5/20 0.35
▸ HTR2A P28223 2/20 0.35
▸ HTR6 P50406 2/20 0.35
▸ HTR3A P46098 1/20 0.35
▸ HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119353 0.78 CA2 (0.35) CA2TP53GAAMAPK1FADS1
SCHEMBL5126113 0.73 PGR (0.40) PBRM1TP53MAPT
SCHEMBL5111570 0.73 HTR5A (0.46) PBRM1SMARCA2SMARCA4TP53HTR5A
SCHEMBL11040315 0.72 CA2 (0.67) CA2FADS1TDP1KMT2A
SCHEMBL11040506 0.71 CA2 (0.47) PBRM1SMARCA2SMARCA4CA2TP53
SCHEMBL11039038 0.71 CA2 (0.55) PBRM1SMARCA2SMARCA4CA2TP53
SCHEMBL5118402 0.70 PBRM1 (0.38) PBRM1SMARCA2SMARCA4TP53GAA
SCHEMBL5119433 0.70 HTR5A (0.47) PBRM1SMARCA2SMARCA4TP53ALDH1A1
SCHEMBL5111455 0.68 SMARCA2 (0.40) PBRM1SMARCA2SMARCA4TP53ALDH1A1
SCHEMBL10500029 0.65 CA2 (0.53) CA2MAPK1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442696-B2 Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses LIGAND PHARMACEUTICALS, INC. (US) 2008-10-28 — — US disclosed
US-20070197520-A1 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES LIGAND PHARMACEUTICALS INC. 2007-08-23 — — US disclosed
WO-2006010142-A2 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE LIGAND PHARMACEUTICALS, INC. (US) 2006-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197520-A1 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES NR3C2, MC2R, NR3C1 PBRM1 2599/4885SMARCA2 3346/4885SMARCA4 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback